alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 30 studies in Health systems and care delivery with an author at University of Southern California (US) (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Health systems and care delivery” covers

Health systems and care delivery — How health systems organise, coordinate and pay for dementia care, and where and how people with dementia actually receive it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population

✓ Peer-reviewed alzhub usefulness score 55 out of 100. The Journal of Prevention of Alzheimer s Disease 2023-10-26

The average detection rates for mild cognitive impairment is 0.08 (interquartile range=0.00-0.02) for both clinicians and practices, suggesting that only about 8% of expected cases were diagnosed on average. 3 key findings →

Participants: 25 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dementia diagnosis and utilization patterns in a racially diverse population within an integrated health care delivery system

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2022-01-01

ADRD prevalence was 5.5%. A total of 25,278 individuals had an incident ADRD code (rate: 1.2%) over the study period-nearly half during a hospital-based encounter. 5 key findings →

Participants: 25,278 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

State Department of Motor Vehicles Reporting Mandates of Dementia Diagnoses and Dementia Underdiagnosis

✓ Peer-reviewed alzhub usefulness score 54 out of 100. JAMA Network Open 2024-04-25

Four states have clinician reporting mandates, 14 have mandates requiring drivers to self-report dementia diagnoses, and 32 states and the District of Columbia do not have explicit requirements. 5 key findings →

Design: cross-sectional Participants: 35 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Trends in Incident Dementia Diagnosis Before and After Medicare Risk Adjustment

✓ Peer-reviewed alzhub usefulness score 50 out of 100. JAMA Network Open 2023-12-15

This cohort study examines rates of new diagnosis of Alzheimer disease and related dementias among beneficiaries of Medicare Advantage plans vs traditional Medicare from 2016 through 2020. 1 key finding →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Primary Care Cost Sharing in Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 50 out of 100. JAMA Health Forum 2026-07-10

Secondary outcomes included plan- and county-level factors associated with offering this benefit in 2025, estimated using multivariable mixed-effects logistic regression with county-level random intercepts. 2 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source

Interdisciplinary Aging Research to Address Health Disparities in Alzheimer’s Disease and Related Dementias: A Scientific Training Program for Early-Career Scholars

✓ Peer-reviewed alzhub usefulness score 49 out of 100. The Journals of Gerontology Series B 2022-10-21

According to the National Institute on Aging (NIA), there are more than 70 associated genes or genetic areas associated with Alzheimer’s when 20 years ago, we knew of only four (Hodes, 2022). 5 key findings →

Design: longitudinal study Participants: 42 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Balancing Burdens and Benefits: Ethical Issues of Off‐Label Prescription Pharmaceutical Use

✓ Peer-reviewed alzhub usefulness score 49 out of 100. PM&R 2013-10-01

He has even given a threshold outlining when the practice of medicine ends versus when the practice of unethical, non–institutional review board approved research begins. 4 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

National trends in the prevalence of dementia in Medicare Advantage and Traditional Medicare

✓ Peer-reviewed alzhub usefulness score 47 out of 100. BMC Health Services Research 2026-03-06

Among TM enrollees, prevalence of dementia was lower by 4% points in 2014 (9.0%, 95%CI: 7.8%, 9.3%) compared to 2000 (13.0%, 95%CI: 12%, 14%). 5 key findings →

Design: cross-sectional Participants: 18,381 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Estimates of diagnosed dementia prevalence and incidence among diverse beneficiaries in traditional Medicare and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2023-07-01

Approximately half of Medicare beneficiaries are enrolled in Medicare Advantage (MA), a private plan alternative to traditional Medicare (TM). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Role of PCPs in diagnosing dementia in traditional Medicare and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia 2025-10-01

Among a matched sample of 15,410,030 beneficiaries, accounting for both provider and patient characteristics, the incident dementia diagnosis rate was 0.11 percentage points lower for MA beneficiaries compared to TM beneficiaries attributed to the same PCP. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

Gridlock in hospital medicine

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Hospital Medicine 2023-12-12

Before the COVID-19 pandemic, supply and demand forcast models predicted significant nursing shortages across the United States through 2030 due to both an aging patient population and nursing workforce.1, 2 However, during the pandemic, we saw an exodus of younger nurses in addition to early retirements. 5 key findings →

Participants: 100 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Structural brain imaging for newly diagnosed cognitive impairment by Medicare coverage type

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of the American College of Radiology : JACR 2026-09-15

Structural brain imaging is guideline-recommended for cases with newly diagnosed cognitive impairment. 2 key findings →

Design: cross-sectional Participants: 1,095,947 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

After Risk-Adjustment Change, Dementia Diagnoses Increased In Medicare Advantage Relative To Traditional Medicare

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Health Affairs 2025-01-01

In 2020, the Centers for Medicare and Medicaid Services reintroduced Alzheimer's disease and related dementias to its risk-adjustment payment model for Medicare Advantage (MA) plans. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Factors associated with high intensity of end‐of‐life care for decedents with dementia in a Medicare Advantage plan

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2022-12-01

We found notable differences in socio‐demographic and clinical characteristics, and utilization patterns in the year prior to death between decedents with dementia who were hospitalized in the last 30 days of life vs. those who were not. 4 key findings →

Participants: 6,299 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Paying for advance care planning in medicare: Impacts on care and spending near end of life

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of health economics 2024-09-16

Spending at end of life (EOL) accounts for a large and growing share of healthcare expenditures in the US, and often reflects aggressive care with questionable value for dying patients. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Estimates of diagnosed dementia prevalence and incidence among diverse beneficiaries in Traditional Medicare and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2023-12-01

Lower diagnosed dementia rates in MA compared to TM may exacerbate racial/ethnic disparities in diagnosed dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Disparities in High-Risk Medication Use—Implications for Health Equity and Deprescribing Practices

✓ Peer-reviewed alzhub usefulness score 36 out of 100. JAMA Network Open 2025-04-14

Potentially inappropriate medication (PIM) use-defined as the use of high-risk medications that can increase the risk of adverse events such as physical, cognitive, and functional decline; delirium; hospitalizations; and mortality-remains a significant concern in older adults in the US.Numerous guidelines, including the American Geriatrics Society Beers Criteria 1 and the STOPP criteria, 2 define PIMs as medications for which the risk of adverse effects outweighs potential benefits or are inappropriate for specific populations or disease states, such dementia or kidney disease.PIM use may be particularly harmful in populations experiencing other health care disparities, as communities experiencing other consequences of health care inequity, including limited access to physicians or pharmacies, greater financial stress, and a higher comorbidity burden, may experience disproportionate effects from the adverse consequences of PIM use. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Promoting Brain Health in the Context of Normal Aging and Mild Cognitive Impairment: A Tutorial

✓ Peer-reviewed alzhub usefulness score 36 out of 100. American journal of speech-language pathology 2026-06-18

There are significant opportunities for speech-language pathologists (SLPs) to play important roles in the primary and secondary prevention of Alzheimer's disease and related dementias (ADRD) beyond current practices. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed